Screener
Denali Therapeutics Inc. DNLI Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$127.55M-2.8% | -$128.45M+3.4% | -$128.55M-12.0% | -$126.9M-18.4% | -$124.12M-25.3% | ||
| $3.57M+17.2% | $2.85M+22.4% | $2.87M+54.7% | $2.95M+60.3% | $3.05M+56.8% | ||
| $22.92M-9.7% | $23.09M-8.2% | $23.95M-4.5% | $25.14M+1.1% | $25.39M+1.1% | ||
| -$97M-28.8% | -$131.2M+0.2% | -$98.54M-17.7% | -$107.3M-81.4% | -$75.3M+17.5% | ||
| $805K-81.2% | $2.47M-51.4% | $1.52M-70.1% | —— | $4.28M-10.6% | ||
| -$104.08M-166% | $94.46M+404% | $20.77M— | $57.83M— | $157.94M— | ||
| $14.98M+823% | $219.04M+5,923% | $192.13M— | -$778K— | $1.62M-76.0% | ||
| -$186.1M-321% | $182.3M+257% | $114.36M+35.6% | -$50.24M— | $84.26M— | ||
| -$97.81M-22.9% | -$133.67M+2.1% | -$100.06M-12.7% | -$105.92M-68.1% | -$79.58M+17.1% |
FAQ
- How much cash does Denali Therapeutics Inc. generate?
- Denali Therapeutics Inc. (DNLI) generated -$434.0M in operating cash flow over the trailing twelve months.
- What is Denali Therapeutics Inc.'s free cash flow?
- After $9.1M of capital expenditures, Denali Therapeutics Inc.'s free cash flow was -$437.5M over the trailing twelve months, down 18.9% year over year.
- Where does Denali Therapeutics Inc.'s cash flow data come from?
- Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
